Drug-resistant TB: latest news

Drug-resistant TB resources

  • Multidrug-resistant tuberculosis

    Some strains of tuberculosis have become resistant to some of the standard drugs. These multidrug-resistant (MDR) strains have infected both people with HIV and HIV-negative...

    From: HIV treatments directory

    Information level Level 4
  • Drug-resistant TB

    TB that is resistant to isoniazid and rifampicin, and to other drugs as well, is becoming much more common. This is called multidrug-resistant TB (MDR-TB)...

    From: Booklets

    Information level Level 2

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound

    Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria.

    12 December 2014 | PR Newswire
  • Drug-resistant infections could lead to 10 million extra deaths a year – report

    The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.

    11 December 2014 | The Guardian
  • Preliminary Data Show High Success Rate for Dramatically Shortened Multidrug-resistant TB Treatment Option

    A nine-month treatment regiment for multidrug-resistant tuberculosis (MDR-TB) appears to be as effective as a 12-month regiment, according to data from two new studies being presented today at the 45th World Conference on Lung Health in Barcelona, Spain.

    31 October 2014 | International Union Against Tuberculosis and Lung Disease
  • WHO interim guidance on the use of delamanid in the treatment of MDR-TB

    A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB

    29 October 2014 | World Health Organization
  • Success short treatment against drug-resistant tuberculosis confirmed

    In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.

    28 October 2014 | Institute of Tropical Medicine
  • UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases

    UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects. UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.

    27 October 2014 | UNITAID
  • Drug-resistant tuberculosis poses global threat, warn doctors

    World Health Organisation says spread of hardier strains of TB across former USSR nations is of ‘critical concern’.

    22 October 2014 | The Guardian
  • South Africa: Bedaquiline approved to treat multi-drug resistant tuberculosis

    The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.

    21 October 2014 | Business Day
  • Minsk has extremely high levels of drug-resistant TB, a study in Belarus reveals

    Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7–42.8) of new patients and 76.5% (95% CI 66.1–86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3–20.7). The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world.

    29 September 2014 | TB Europe Coalition
  • What does new drug PaMZ mean for TB and HIV treatment?

    The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

    02 September 2014 | The Guardian
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also